VIU-T 0.57 XMU-T 0.75 EQL-T 0.3 EXPE-Q 1.01 AAPL-Q 7.73 HSUV.U-T 0.02
Daily Stock Opinions and Ratings
Stockchase Opinions

Geoff Houlton Telesta Therapeutics Inc TST-T BUY Mar 26, 2008

A very interesting company. Has an animal health product, human health products focused on bladder cancer and a vaccine for cattle. Likes the company, has existing products (short-term revenue stream) and has future opportunity and a potential blockbuster product. A significant opportunity.
Geoff HoultonGeoff Houlton
No
Unlock Rating
$0.920

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

WATCH

Telesta Therapeutics Inc(TST-T)

Oct 18, 2007
He has done very poorly in this area. This company is on their watch list, but they aren't buying yet. As it's down from where the caller bought, he would be looking at using it as a tax loss.
Benj GallanderBenj Gallander
Unknown
Unlock Rating
$0.780

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Telesta Therapeutics Inc(TST-T)

May 07, 2008
A vaccine that is used in cattle to reduce E. coli. The question is, does it immunize enough. Very promising. Very stable revenue. Trading at only 2X sales so you get their cancer and cattle products for free.
Serge DepatieSerge Depatie
No
Unlock Rating
$0.810

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Telesta Therapeutics Inc(TST-T)

Oct 04, 2011
Losing money. Have a negative cash flow of about $1 million a month, which could continue possibly the end of 2012. This is a real danger signal.
Benj GallanderBenj Gallander
No
Unlock Rating
$0.540

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

Telesta Therapeutics Inc(TST-T)

Apr 17, 2012
Impressive company but not impressive enough to buy. Have a number of problems that they still have to deal with. Has the potential of a good turnaround play.
Benj GallanderBenj Gallander
No
Unlock Rating
$0.570

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Telesta Therapeutics Inc(TST-T)

Sep 26, 2013

On his Stock Watch list. He knows there have been some agreements between management and some of the investors, which he feels bodes well for the company. At this point in time, he is not willing to jump in. They still have to deal with some internal things before it would be of more interest to him.

Benj GallanderBenj Gallander
No
Unlock Rating
$0.275

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

XMLV-N 0.87$58.2
IJH-N 0.69$54.37
VPL-N 1.89$70.12
VGK-N 1.78$68.29
ZUE-T 1.26$73.65
Advertising

Today's Top Picks

VIU-T 0.57$34.52
XMU-T 0.75$83.96
EQL-T 0.3$34.19
EXPE-Q 1.01$150.53
AAPL-Q 7.73$198.15

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

LSPD-T 0.37$12.7
XAW-T 0.56$40.94
PLTR-Q -0.04$88.55
VOO-N 8.49$490.55
ADBE-Q 2.42$352.47

Most Recent Experts

Mike Philbrick

ReSolve Asset Management

Stockchase Insights

5i Research

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Advertising
Advertising
© Stockchase Inc.